Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. 2017

Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical and Biomolecular Engineering, The University of Melbourne , Parkville, Victoria 3010, Australia.

Despite the immense public health successes of immunization over the past century, effective vaccines are still lacking for globally important pathogens such as human immunodeficiency virus, malaria, and tuberculosis. Exciting recent advances in immunology and biotechnology over the past few decades have facilitated a shift from empirical to rational vaccine design, opening possibilities for improved vaccines. Some of the most important advancements include (i) the purification of subunit antigens with high safety profiles, (ii) the identification of innate pattern recognition receptors (PRRs) and cognate agonists responsible for inducing immune responses, and (iii) developments in nano- and microparticle fabrication and characterization techniques. Advances in particle engineering now allow highly tunable physicochemical properties of particle-based vaccines, including composition, size, shape, surface characteristics, and degradability. Enhanced collaborative efforts between researchers in immunology and materials science are expected to rise to next-generation vaccines. This process will be significantly aided by a greater understanding of the immunological principles guiding vaccine antigenicity, immunogenicity, and efficacy. With specific emphasis on PRR-targeted adjuvants and particle physicochemical properties, this review aims to provide an overview of the current literature to guide and focus rational particle-based vaccine design efforts.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070576 NLR Proteins Intracellular signaling proteins that are defined by the presence of a NUCLEOTIDE-binding region and LEUCINE-rich repeats. Their general structure consists of any of a variety of effector domains at their N-termini such as a caspase recruitment domain (CARD), a central nucleotide-binding domain, and a variable number of C-terminal leucine-rich repeats. They are important for pathogen recognition in the INNATE IMMUNE RESPONSE of animals and plants. Members of the NLR protein family include the NOD SIGNALING ADAPTOR PROTEINS. NOD-like Receptor,Nucleotide-Binding Domain Leucine-Rich Repeat Protein,NLR Protein,NOD-like Receptors,Nucleotide-binding Domain Leucine-rich Repeat Proteins,NOD like Receptor,NOD like Receptors,Nucleotide Binding Domain Leucine Rich Repeat Protein,Nucleotide binding Domain Leucine rich Repeat Proteins,Protein, NLR,Proteins, NLR,Receptor, NOD-like,Receptors, NOD-like
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014612 Vaccines Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases. Vaccine
D014771 Virion The infective system of a virus, composed of the viral genome, a protein core, and a protein coat called a capsid, which may be naked or enclosed in a lipoprotein envelope called the peplos. Virus Particle,Viral Particle,Viral Particles,Particle, Viral,Particle, Virus,Particles, Viral,Particles, Virus,Virions,Virus Particles
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug
D051193 Toll-Like Receptors A family of pattern recognition receptors characterized by an extracellular leucine-rich domain and a cytoplasmic domain that share homology with the INTERLEUKIN 1 RECEPTOR and the DROSOPHILA toll protein. Following pathogen recognition, toll-like receptors recruit and activate a variety of SIGNAL TRANSDUCING ADAPTOR PROTEINS. Receptors, Toll-Like,Toll-Like Receptor,Receptor, Toll-Like,Receptors, Toll Like,Toll Like Receptor,Toll Like Receptors

Related Publications

Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
May 2015, Bioconjugate chemistry,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
June 2020, Molecular pharmaceutics,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
January 1994, Journal of esthetic dentistry,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
July 2016, Annual review of biomedical engineering,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
July 2016, Journal of biomedical nanotechnology,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
June 2019, The Journal of organic chemistry,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
August 2011, Zhongguo zhen jiu = Chinese acupuncture & moxibustion,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
March 2009, Microbial biotechnology,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
December 2003, Annals of biomedical engineering,
Katelyn T Gause, and Adam K Wheatley, and Jiwei Cui, and Yan Yan, and Stephen J Kent, and Frank Caruso
February 2014, Nanomedicine (London, England),
Copied contents to your clipboard!